RTP Mobile Logo
Oncology Today with Dr Neil Love: Key Presentations on Gynecologic Cancers from the 2021 ASCO Annual Meeting (Video Presentation)
Released September 2021

Featuring an interview with Dr Kathleen Moore. Published September 2, 2021. (Video Presentation)

CE Information and Faculty Disclosures

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gynecologic cancers.


    • Consider available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer, and counsel appropriate patients regarding personalized treatment recommendations.
    • Appreciate the biologic rationale for and published clinical trial data with PARP inhibitors in combination with other systemic therapies, and consider the clinical and research implications for ovarian cancer management.
    • Review available and emerging data with anti-PD-1/PD-L1 antibodies for patients with microsatellite instability-high and microsatellite-stable recurrent endometrial cancer, and appreciate ongoing research efforts to define the role of these agents in therapy for this disease.
    • Consider the recent FDA approval of and emerging Phase III data with pembrolizumab in combination with lenvatinib for patients with advanced endometrial cancer who have experienced disease progression after prior systemic therapy, and optimally integrate this novel regimen into clinical management algorithms.
    • Appraise the clinical research findings supporting the use of anti-PD-1/PD-L1 agents for metastatic cervical cancer (CC), and counsel appropriate patients about the risks and potential benefits of this approach.
    • Recognize the incidence of tissue factor expression in patients with CC, and consider published research findings with and the potential role of tisotumab vedotin in therapy for recurrent CC.
    • Recall recent results and ongoing clinical trials evaluating novel agents and strategies for gynecologic cancers, and counsel appropriate patients about participation in research opportunities.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Kathleen Moore, MD
    The Virginia Kerley Cade Endowed Chair in Cancer Development
    Associate Director, Clinical Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor, Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Consulting Agreements: Aravive Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Elevar Therapeutics, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Mersana Therapeutics, Myriad Genetic Laboratories Inc, Sorrento Therapeutics, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Contracted Research: PTC Therapeutics, US Department of Defense.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Genmab and Seagen Inc.

    Release date: September 2021
    Expiration date: September 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):